# Reviewer input, day 2026-11-10
Output file to write: /home/user/news-market-analysis/data/paper/run/2026-11-10/reviewer_output.json

# Handoff from the previous run (read first)
WARNING: PENDING ORDERS in the last note: reconcile with the broker before any new order
Run eu-rev-2026-11-10-01 (decision day 2026-11-10, data cutoff 2026-11-10)
What changed: Infineon reported a record Q4 and guided FY2027 revenue growth above 20% with higher profitability, above forecasts; I sent a buy of 6 IFX.DE for a 10-day horizon. Trump said the Iran war is 'effectively over' and crude fell again; Bayer won FDA approval for asundexian and the FDA ordered a blindness warning on GLP-1 drugs. US CPI is due today; the BofA chip downgrade names were still not confirmed by any item in today's brief.
Holdings and reasons:
- oil_gas: flat | Iran de-escalation keeps pushing crude down; buybacks are routine.
- gold_miners: flat | No name-specific catalyst and high UK costs ahead of CPI.
- chips: long IFX.DE since 2026-11-10, 10 days (order sent, fill not yet seen) | Record Q4 and FY2027 guidance above forecasts at the lowest-cost name.
- pharma: flat | Bayer approval likely expected and was 0.50, just below the bar; the Novo warning is negative.
- copper_uranium: flat | Flat copper, weak China spot demand, no name-specific catalyst.
Open storylines:
- [open] Infineon FY2026 Q4 beat and FY2027 guidance: Watch the opening gap and fill price, the earnings-call tone on cash flow, and any read-across to STMPA.PA; close if the guidance is walked back.
- [open] US CPI release: Due 2026-11-10; check the reaction in chips, gold and copper before any new metals entry and for risk to IFX.DE.
- [fading] Iran risk premium in crude: Trump says the war is 'effectively over' and Hormuz LNG traffic is at a high; watch for a rhetoric reversal or Brent stabilising near 90.
- [open] BofA downgrade of 3 European chip stocks on memory exposure: Names still unconfirmed from a primary source; check whether IFX.DE was among them.
- [open] Bayer asundexian FDA approval: Watch the BAYN.DE price reaction and analyst sales estimates; a launch-focused upgrade could be a catalyst on a later run.
- [open] FDA blindness warning on weight-loss drugs: Negative for NOVO-B.CO; watch for prescription data or further regulatory action.
- [open] FDA probe of Novartis gene therapy: No update today; watch for any regulatory action on NOVN.SW products.
- [fading] US-China trade truce extension and metals rally: Copper flat today with weak China spot demand; need name-specific production or guidance news.
- [open] Nvidia board probe of CEO: No update today; escalation would hurt chips sentiment and IFX.DE.
Pending orders: [{"symbol": "IFX.DE", "side": "BUY", "qty": 6, "status": "sent, no fill seen"}]
EXACT NEXT JOB: Next run: confirm the IFX.DE fill (price and cost) and hold it unless the guidance catalyst is gone; read the US CPI reaction; confirm the BofA chip downgrade names from a primary source. Then re-check the other four themes for a primary-source, name-specific catalyst whose expected move is well above twice the entry cost (watch BAYN.DE follow-through on asundexian). If flat, state per theme what catalyst would have been enough.

# Outcomes of your past trades
No trade has closed yet. Nothing to learn from yet; do not invent lessons.

# Shadow call results (scored calls, no money)
None scored yet (0 calls waiting for their horizon). Nothing to learn from yet.

Account: equity 986.43 EUR, cash 692.13 EUR, start 1000.00 EUR, total -1.36%.
Open positions:
- IFX.DE Infineon x6 entry 50.90 EUR now 49.05 EUR, opened 2026-11-10, exit by 2026-11-24, theme chips, catalyst quoted: Infineon closes FY 2026 with record quarter; expects revenue growth of more than 20 percent and a 5-
Pending orders: none

## Day report (from the close job)
{
 "date": "2026-11-10",
 "equity": 986.43,
 "day_pnl_eur": -13.57,
 "day_pnl_pct": -1.36,
 "total_pnl_pct": -1.36,
 "cash": 692.129,
 "custody_today": 0.001,
 "positions": [
  {
   "symbol": "IFX.DE",
   "qty": 6,
   "exit_by": "2026-11-24"
  }
 ],
 "fills_today": [
  {
   "id": 1,
   "order_id": "20261110-IFX.DE-BUY",
   "time": "2026-11-10T08:15:00Z",
   "symbol": "IFX.DE",
   "side": "BUY",
   "qty": 6,
   "price": 50.8953,
   "currency": "EUR",
   "fee_eur": 2.5,
   "gross_eur": 305.37,
   "costs": {
    "commission": 2.5,
    "fx": 0.0,
    "tax": 0.0,
    "total": 2.5
   },
   "realized_eur": null,
   "catalyst": "Infineon closes FY 2026 with record quarter; expects revenue growth of more than 20 percent and a 5-percentage-point increase in profitability for FY 2027 - marketscreener (corroborated by Bloomberg and WSJ 'Lifts AI Sales Goal') - 2026-11-10",
   "agent": "A-opus-learning",
   "source": "agent",
   "theme": "chips"
  }
 ],
 "reconcile": "consistent",
 "warnings": []
}

## Orders and fills today
{"id": "20261110-IFX.DE-BUY", "time": "2026-11-10T07:09:24Z", "symbol": "IFX.DE", "side": "BUY", "qty": 6, "type": "MARKET", "limit": null, "status": "FILLED", "reasons": [], "source": "agent", "theme": "chips", "catalyst": "Infineon closes FY 2026 with record quarter; expects revenue growth of more than 20 percent and a 5-percentage-point increase in profitability for FY 2027 - marketscreener (corroborated by Bloomberg and WSJ 'Lifts AI Sales Goal') - 2026-11-10", "confidence": 0.54, "horizon": 10, "agent": "A-opus-learning"}
{"id": 1, "order_id": "20261110-IFX.DE-BUY", "time": "2026-11-10T08:15:00Z", "symbol": "IFX.DE", "side": "BUY", "qty": 6, "price": 50.8953, "currency": "EUR", "fee_eur": 2.5, "gross_eur": 305.37, "costs": {"commission": 2.5, "fx": 0.0, "tax": 0.0, "total": 2.5}, "realized_eur": null, "catalyst": "Infineon closes FY 2026 with record quarter; expects revenue growth of more than 20 percent and a 5-percentage-point increase in profitability for FY 2027 - marketscreener (corroborated by Bloomberg and WSJ 'Lifts AI Sales Goal') - 2026-11-10", "agent": "A-opus-learning", "source": "agent", "theme": "chips"}